Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection Article Swipe
Yuta Yokoyama
,
Eiji Nozawa
,
Miho Morita
,
Emi Ishikawa
,
Takehiko Mori
,
Masatoshi Sakurai
,
Taku Kikuchi
,
Eri Matsuki
,
Rie Yamazaki
,
Keisuke Kataoka
,
Aya Jibiki
,
Hitoshi Kawazoe
,
Sayo Suzuki
,
Tomonori Nakamura
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1002/jcla.24598
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1002/jcla.24598
Background Dasatinib, nilotinib, and bosutinib, second‐generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third‐generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography‐tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high‐performance liquid chromatography (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC analytical method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Methods Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid‐phase extraction. The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. Results The calibration ranges were 2–500 ng/ml for dasatinib, 100–5000 ng/ml for nilotinib, and 10–500 ng/ml for bosutinib and ponatinib. Intra‐day and inter‐day precision and accuracy values were found to be in accordance with the U.S. Food and Drug Administration guidelines. The recovery rates were 92.9%–96.0%, 80.7%–86.1%, 91.6%–99.0%, and 86.4%–92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Conclusion To the best of our knowledge, this is the first report of an HPLC‐PDA analytical method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clinical practice.
Related Topics
Concepts
Nilotinib
Bosutinib
Dasatinib
Ponatinib
Chromatography
High-performance liquid chromatography
Chemistry
Medicine
Pharmacology
Myeloid leukemia
Imatinib
Cancer research
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/jcla.24598
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598
- OA Status
- gold
- Cited By
- 10
- References
- 29
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4285077252
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4285077252Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/jcla.24598Digital Object Identifier
- Title
-
Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detectionWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-07-12Full publication date if available
- Authors
-
Yuta Yokoyama, Eiji Nozawa, Miho Morita, Emi Ishikawa, Takehiko Mori, Masatoshi Sakurai, Taku Kikuchi, Eri Matsuki, Rie Yamazaki, Keisuke Kataoka, Aya Jibiki, Hitoshi Kawazoe, Sayo Suzuki, Tomonori NakamuraList of authors in order
- Landing page
-
https://doi.org/10.1002/jcla.24598Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598Direct OA link when available
- Concepts
-
Nilotinib, Bosutinib, Dasatinib, Ponatinib, Chromatography, High-performance liquid chromatography, Chemistry, Medicine, Pharmacology, Myeloid leukemia, Imatinib, Cancer researchTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 5, 2023: 3, 2022: 1Per-year citation counts (last 5 years)
- References (count)
-
29Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4285077252 |
|---|---|
| doi | https://doi.org/10.1002/jcla.24598 |
| ids.doi | https://doi.org/10.1002/jcla.24598 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35819095 |
| ids.openalex | https://openalex.org/W4285077252 |
| fwci | 2.24549132 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000814 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Aniline Compounds |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000970 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Antineoplastic Agents |
| mesh[2].qualifier_ui | Q000379 |
| mesh[2].descriptor_ui | D002851 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | methods |
| mesh[2].descriptor_name | Chromatography, High Pressure Liquid |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D000069439 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Dasatinib |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006801 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Humans |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D007093 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Imidazoles |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D015464 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D009570 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Nitriles |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D047428 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Protein Kinase Inhibitors |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D011724 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Pyridazines |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D011743 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Pyrimidines |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D011804 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Quinolines |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000814 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Aniline Compounds |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D000970 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Antineoplastic Agents |
| mesh[14].qualifier_ui | Q000379 |
| mesh[14].descriptor_ui | D002851 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | methods |
| mesh[14].descriptor_name | Chromatography, High Pressure Liquid |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D000069439 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Dasatinib |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D007093 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Imidazoles |
| mesh[18].qualifier_ui | Q000188 |
| mesh[18].descriptor_ui | D015464 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | drug therapy |
| mesh[18].descriptor_name | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D009570 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Nitriles |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D047428 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Protein Kinase Inhibitors |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D011724 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Pyridazines |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D011743 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Pyrimidines |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D011804 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Quinolines |
| type | article |
| title | Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection |
| biblio.issue | 8 |
| biblio.volume | 36 |
| biblio.last_page | e24598 |
| biblio.first_page | e24598 |
| topics[0].id | https://openalex.org/T11215 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Chronic Myeloid Leukemia Treatments |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9991999864578247 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T10950 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9962000250816345 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2739 |
| topics[2].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[2].display_name | Acute Lymphoblastic Leukemia research |
| is_xpac | False |
| apc_list.value | 3850 |
| apc_list.currency | USD |
| apc_list.value_usd | 3850 |
| apc_paid.value | 3850 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3850 |
| concepts[0].id | https://openalex.org/C2777413986 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9503306150436401 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412327 |
| concepts[0].display_name | Nilotinib |
| concepts[1].id | https://openalex.org/C2778208673 |
| concepts[1].level | 5 |
| concepts[1].score | 0.9383812546730042 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q894611 |
| concepts[1].display_name | Bosutinib |
| concepts[2].id | https://openalex.org/C2779536868 |
| concepts[2].level | 4 |
| concepts[2].score | 0.9252842664718628 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q419940 |
| concepts[2].display_name | Dasatinib |
| concepts[3].id | https://openalex.org/C2780381907 |
| concepts[3].level | 5 |
| concepts[3].score | 0.9019231200218201 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q198728 |
| concepts[3].display_name | Ponatinib |
| concepts[4].id | https://openalex.org/C43617362 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6182556748390198 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[4].display_name | Chromatography |
| concepts[5].id | https://openalex.org/C179998833 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5354402661323547 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q381233 |
| concepts[5].display_name | High-performance liquid chromatography |
| concepts[6].id | https://openalex.org/C185592680 |
| concepts[6].level | 0 |
| concepts[6].score | 0.3904218375682831 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[6].display_name | Chemistry |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.33933210372924805 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C98274493 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3314628601074219 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[8].display_name | Pharmacology |
| concepts[9].id | https://openalex.org/C2778729363 |
| concepts[9].level | 2 |
| concepts[9].score | 0.28539222478866577 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11688946 |
| concepts[9].display_name | Myeloid leukemia |
| concepts[10].id | https://openalex.org/C2777583451 |
| concepts[10].level | 3 |
| concepts[10].score | 0.16188979148864746 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q177094 |
| concepts[10].display_name | Imatinib |
| concepts[11].id | https://openalex.org/C502942594 |
| concepts[11].level | 1 |
| concepts[11].score | 0.14368906617164612 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[11].display_name | Cancer research |
| keywords[0].id | https://openalex.org/keywords/nilotinib |
| keywords[0].score | 0.9503306150436401 |
| keywords[0].display_name | Nilotinib |
| keywords[1].id | https://openalex.org/keywords/bosutinib |
| keywords[1].score | 0.9383812546730042 |
| keywords[1].display_name | Bosutinib |
| keywords[2].id | https://openalex.org/keywords/dasatinib |
| keywords[2].score | 0.9252842664718628 |
| keywords[2].display_name | Dasatinib |
| keywords[3].id | https://openalex.org/keywords/ponatinib |
| keywords[3].score | 0.9019231200218201 |
| keywords[3].display_name | Ponatinib |
| keywords[4].id | https://openalex.org/keywords/chromatography |
| keywords[4].score | 0.6182556748390198 |
| keywords[4].display_name | Chromatography |
| keywords[5].id | https://openalex.org/keywords/high-performance-liquid-chromatography |
| keywords[5].score | 0.5354402661323547 |
| keywords[5].display_name | High-performance liquid chromatography |
| keywords[6].id | https://openalex.org/keywords/chemistry |
| keywords[6].score | 0.3904218375682831 |
| keywords[6].display_name | Chemistry |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.33933210372924805 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/pharmacology |
| keywords[8].score | 0.3314628601074219 |
| keywords[8].display_name | Pharmacology |
| keywords[9].id | https://openalex.org/keywords/myeloid-leukemia |
| keywords[9].score | 0.28539222478866577 |
| keywords[9].display_name | Myeloid leukemia |
| keywords[10].id | https://openalex.org/keywords/imatinib |
| keywords[10].score | 0.16188979148864746 |
| keywords[10].display_name | Imatinib |
| keywords[11].id | https://openalex.org/keywords/cancer-research |
| keywords[11].score | 0.14368906617164612 |
| keywords[11].display_name | Cancer research |
| language | en |
| locations[0].id | doi:10.1002/jcla.24598 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S28295008 |
| locations[0].source.issn | 0887-8013, 1098-2825 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 0887-8013 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal of Clinical Laboratory Analysis |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Clinical Laboratory Analysis |
| locations[0].landing_page_url | https://doi.org/10.1002/jcla.24598 |
| locations[1].id | pmid:35819095 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of clinical laboratory analysis |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35819095 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9396206 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | J Clin Lab Anal |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9396206 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5001263306 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9359-9945 |
| authorships[0].author.display_name | Yuta Yokoyama |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[0].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[0].affiliations[1].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I203951103 |
| authorships[0].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Keio University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Yuta Yokoyama |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan, Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[1].author.id | https://openalex.org/A5021848933 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Eiji Nozawa |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[1].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I203951103 |
| authorships[1].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Keio University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Eiji Nozawa |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[2].author.id | https://openalex.org/A5111120482 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Miho Morita |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I203951103 |
| authorships[2].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Keio University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Miho Morita |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[3].author.id | https://openalex.org/A5060726479 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8802-9438 |
| authorships[3].author.display_name | Emi Ishikawa |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[3].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I203951103 |
| authorships[3].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Keio University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Emi Ishikawa |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[4].author.id | https://openalex.org/A5051983260 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8176-4760 |
| authorships[4].author.display_name | Takehiko Mori |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I125602781 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[4].affiliations[1].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I203951103 |
| authorships[4].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Keio University |
| authorships[4].institutions[1].id | https://openalex.org/I125602781 |
| authorships[4].institutions[1].ror | https://ror.org/051k3eh31 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I125602781 |
| authorships[4].institutions[1].country_code | JP |
| authorships[4].institutions[1].display_name | Tokyo Medical and Dental University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Takehiko Mori |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan, Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[5].author.id | https://openalex.org/A5025009369 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6687-4136 |
| authorships[5].author.display_name | Masatoshi Sakurai |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[5].affiliations[0].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I203951103 |
| authorships[5].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Keio University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Masatoshi Sakurai |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[6].author.id | https://openalex.org/A5006067564 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-3210-7756 |
| authorships[6].author.display_name | Taku Kikuchi |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[6].affiliations[0].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I203951103 |
| authorships[6].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Keio University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Taku Kikuchi |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[7].author.id | https://openalex.org/A5081878134 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Eri Matsuki |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[7].affiliations[0].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I203951103 |
| authorships[7].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Keio University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Eri Matsuki |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[8].author.id | https://openalex.org/A5003368425 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-7489-4180 |
| authorships[8].author.display_name | Rie Yamazaki |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[8].affiliations[0].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[8].affiliations[1].raw_affiliation_string | Center for Transfusion Medicine and Cell Therapy, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I203951103 |
| authorships[8].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Keio University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Rie Yamazaki |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Center for Transfusion Medicine and Cell Therapy, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[9].author.id | https://openalex.org/A5024179981 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8263-9902 |
| authorships[9].author.display_name | Keisuke Kataoka |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[9].affiliations[0].raw_affiliation_string | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I203951103 |
| authorships[9].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Keio University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Keisuke Kataoka |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan |
| authorships[10].author.id | https://openalex.org/A5012738684 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-9478-7419 |
| authorships[10].author.display_name | Aya Jibiki |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[10].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[10].institutions[0].id | https://openalex.org/I203951103 |
| authorships[10].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Keio University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Aya Jibiki |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[11].author.id | https://openalex.org/A5040308892 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-0626-7908 |
| authorships[11].author.display_name | Hitoshi Kawazoe |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[11].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[11].affiliations[1].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[11].institutions[0].id | https://openalex.org/I203951103 |
| authorships[11].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Keio University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Hitoshi Kawazoe |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan, Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[12].author.id | https://openalex.org/A5051149857 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-3094-104X |
| authorships[12].author.display_name | Sayo Suzuki |
| authorships[12].countries | JP |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[12].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[12].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[12].affiliations[1].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[12].institutions[0].id | https://openalex.org/I203951103 |
| authorships[12].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[12].institutions[0].country_code | JP |
| authorships[12].institutions[0].display_name | Keio University |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Sayo Suzuki |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan, Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[13].author.id | https://openalex.org/A5016183139 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-6955-5897 |
| authorships[13].author.display_name | Tomonori Nakamura |
| authorships[13].countries | JP |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I203951103 |
| authorships[13].affiliations[0].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| authorships[13].affiliations[1].institution_ids | https://openalex.org/I203951103 |
| authorships[13].affiliations[1].raw_affiliation_string | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan |
| authorships[13].institutions[0].id | https://openalex.org/I203951103 |
| authorships[13].institutions[0].ror | https://ror.org/02kn6nx58 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I203951103 |
| authorships[13].institutions[0].country_code | JP |
| authorships[13].institutions[0].display_name | Keio University |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Tomonori Nakamura |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan, Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11215 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Chronic Myeloid Leukemia Treatments |
| related_works | https://openalex.org/W4280502786, https://openalex.org/W1972280313, https://openalex.org/W2078327579, https://openalex.org/W4246242006, https://openalex.org/W4283524715, https://openalex.org/W3189669651, https://openalex.org/W2531370518, https://openalex.org/W2802017747, https://openalex.org/W2008126849, https://openalex.org/W34826755 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 3 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1002/jcla.24598 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S28295008 |
| best_oa_location.source.issn | 0887-8013, 1098-2825 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 0887-8013 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal of Clinical Laboratory Analysis |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_lineage_names | Wiley |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Clinical Laboratory Analysis |
| best_oa_location.landing_page_url | https://doi.org/10.1002/jcla.24598 |
| primary_location.id | doi:10.1002/jcla.24598 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S28295008 |
| primary_location.source.issn | 0887-8013, 1098-2825 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 0887-8013 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal of Clinical Laboratory Analysis |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcla.24598 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Clinical Laboratory Analysis |
| primary_location.landing_page_url | https://doi.org/10.1002/jcla.24598 |
| publication_date | 2022-07-12 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W2127754229, https://openalex.org/W2143939343, https://openalex.org/W2397234997, https://openalex.org/W2260921597, https://openalex.org/W2156145496, https://openalex.org/W2766187515, https://openalex.org/W2110648386, https://openalex.org/W2886320425, https://openalex.org/W7073854651, https://openalex.org/W2076678352, https://openalex.org/W2801409342, https://openalex.org/W2495072828, https://openalex.org/W2162139090, https://openalex.org/W2198249244, https://openalex.org/W2770262472, https://openalex.org/W2553089427, https://openalex.org/W2979907690, https://openalex.org/W2993115100, https://openalex.org/W2769074136, https://openalex.org/W2113775648, https://openalex.org/W2775819627, https://openalex.org/W2161643380, https://openalex.org/W2395842947, https://openalex.org/W2165214766, https://openalex.org/W2604630375, https://openalex.org/W2013829602, https://openalex.org/W2609843407, https://openalex.org/W2018627521, https://openalex.org/W4285077252 |
| referenced_works_count | 29 |
| abstract_inverted_index.a | 13, 50, 79, 122 |
| abstract_inverted_index.10 | 119 |
| abstract_inverted_index.To | 185 |
| abstract_inverted_index.We | 217 |
| abstract_inverted_index.an | 73, 197 |
| abstract_inverted_index.be | 157 |
| abstract_inverted_index.by | 97, 108 |
| abstract_inverted_index.in | 20, 41, 47, 116, 158, 210, 232, 236 |
| abstract_inverted_index.is | 192 |
| abstract_inverted_index.of | 23, 37, 88, 100, 188, 196, 206, 213, 228 |
| abstract_inverted_index.to | 69, 156 |
| abstract_inverted_index.CML | 235 |
| abstract_inverted_index.The | 111, 128, 168 |
| abstract_inverted_index.and | 4, 11, 71, 140, 145, 148, 151, 164, 175, 181 |
| abstract_inverted_index.are | 16 |
| abstract_inverted_index.can | 224 |
| abstract_inverted_index.for | 34, 84, 134, 138, 143, 177 |
| abstract_inverted_index.has | 61 |
| abstract_inverted_index.min | 120 |
| abstract_inverted_index.not | 62 |
| abstract_inverted_index.our | 189 |
| abstract_inverted_index.the | 21, 38, 48, 85, 89, 104, 161, 186, 193, 207, 211, 220, 226 |
| abstract_inverted_index.yet | 63 |
| abstract_inverted_index.CML. | 216 |
| abstract_inverted_index.Drug | 165 |
| abstract_inverted_index.Food | 163 |
| abstract_inverted_index.HPLC | 75, 124 |
| abstract_inverted_index.TKI, | 15 |
| abstract_inverted_index.TKIs | 40, 113, 209 |
| abstract_inverted_index.This | 66 |
| abstract_inverted_index.U.S. | 162 |
| abstract_inverted_index.aims | 68 |
| abstract_inverted_index.been | 45, 64 |
| abstract_inverted_index.best | 187 |
| abstract_inverted_index.drug | 230 |
| abstract_inverted_index.four | 39, 90, 105, 112, 208 |
| abstract_inverted_index.have | 44 |
| abstract_inverted_index.mass | 31 |
| abstract_inverted_index.that | 56, 201, 219 |
| abstract_inverted_index.this | 191 |
| abstract_inverted_index.used | 19 |
| abstract_inverted_index.were | 95, 114, 131, 154, 171 |
| abstract_inverted_index.with | 160, 215, 234 |
| abstract_inverted_index.(PDA) | 82 |
| abstract_inverted_index.TKIs, | 106 |
| abstract_inverted_index.TKIs. | 91 |
| abstract_inverted_index.array | 81 |
| abstract_inverted_index.assay | 55 |
| abstract_inverted_index.first | 194 |
| abstract_inverted_index.found | 155 |
| abstract_inverted_index.human | 42 |
| abstract_inverted_index.ng/ml | 133, 137, 142 |
| abstract_inverted_index.order | 117 |
| abstract_inverted_index.rates | 170 |
| abstract_inverted_index.serum | 43, 101, 212 |
| abstract_inverted_index.study | 67 |
| abstract_inverted_index.these | 59 |
| abstract_inverted_index.using | 78, 121 |
| abstract_inverted_index.(CML). | 27 |
| abstract_inverted_index.(HPLC) | 54 |
| abstract_inverted_index.allows | 202 |
| abstract_inverted_index.assays | 33 |
| abstract_inverted_index.binary | 123 |
| abstract_inverted_index.eluted | 115 |
| abstract_inverted_index.herein | 223 |
| abstract_inverted_index.kinase | 8 |
| abstract_inverted_index.liquid | 29, 52 |
| abstract_inverted_index.method | 77, 200, 221 |
| abstract_inverted_index.ranges | 130 |
| abstract_inverted_index.report | 195 |
| abstract_inverted_index.serial | 98 |
| abstract_inverted_index.values | 153 |
| abstract_inverted_index.within | 118 |
| abstract_inverted_index.(TKIs), | 10 |
| abstract_inverted_index.2–500 | 132 |
| abstract_inverted_index.Methods | 92 |
| abstract_inverted_index.Results | 127 |
| abstract_inverted_index.believe | 218 |
| abstract_inverted_index.chronic | 24 |
| abstract_inverted_index.improve | 225 |
| abstract_inverted_index.myeloid | 25 |
| abstract_inverted_index.samples | 102 |
| abstract_inverted_index.system. | 126 |
| abstract_inverted_index.10–500 | 141 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Although | 28 |
| abstract_inverted_index.accuracy | 152 |
| abstract_inverted_index.approved | 17 |
| abstract_inverted_index.clinical | 237 |
| abstract_inverted_index.detector | 83 |
| abstract_inverted_index.dilution | 99 |
| abstract_inverted_index.followed | 107 |
| abstract_inverted_index.gradient | 125 |
| abstract_inverted_index.leukemia | 26 |
| abstract_inverted_index.patients | 214, 233 |
| abstract_inverted_index.prepared | 96 |
| abstract_inverted_index.recovery | 169 |
| abstract_inverted_index.reported | 46 |
| abstract_inverted_index.tyrosine | 7 |
| abstract_inverted_index.validate | 72 |
| abstract_inverted_index.bosutinib | 144 |
| abstract_inverted_index.compounds | 60 |
| abstract_inverted_index.developed | 222 |
| abstract_inverted_index.efficient | 74, 203 |
| abstract_inverted_index.establish | 70 |
| abstract_inverted_index.practice. | 238 |
| abstract_inverted_index.precision | 150 |
| abstract_inverted_index.standards | 94 |
| abstract_inverted_index.treatment | 22 |
| abstract_inverted_index.100–5000 | 136 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 184 |
| abstract_inverted_index.Dasatinib, | 2 |
| abstract_inverted_index.HPLC‐PDA | 198 |
| abstract_inverted_index.accordance | 159 |
| abstract_inverted_index.analytical | 76, 199 |
| abstract_inverted_index.bosutinib, | 5, 180 |
| abstract_inverted_index.containing | 103 |
| abstract_inverted_index.dasatinib, | 135, 178 |
| abstract_inverted_index.developed. | 65 |
| abstract_inverted_index.efficiency | 227 |
| abstract_inverted_index.inhibitors | 9 |
| abstract_inverted_index.knowledge, | 190 |
| abstract_inverted_index.monitoring | 231 |
| abstract_inverted_index.nilotinib, | 3, 139, 179 |
| abstract_inverted_index.photodiode | 80 |
| abstract_inverted_index.ponatinib, | 12, 182 |
| abstract_inverted_index.ponatinib. | 146 |
| abstract_inverted_index.quantifies | 58 |
| abstract_inverted_index.Calibration | 93 |
| abstract_inverted_index.Intra‐day | 147 |
| abstract_inverted_index.calibration | 129 |
| abstract_inverted_index.extraction. | 110 |
| abstract_inverted_index.guidelines. | 167 |
| abstract_inverted_index.inter‐day | 149 |
| abstract_inverted_index.literature, | 49 |
| abstract_inverted_index.therapeutic | 229 |
| abstract_inverted_index.simultaneous | 35, 86, 204 |
| abstract_inverted_index.spectrometry | 32 |
| abstract_inverted_index.86.4%–92.6% | 176 |
| abstract_inverted_index.respectively. | 183 |
| abstract_inverted_index.solid‐phase | 109 |
| abstract_inverted_index.80.7%–86.1%, | 173 |
| abstract_inverted_index.91.6%–99.0%, | 174 |
| abstract_inverted_index.92.9%–96.0%, | 172 |
| abstract_inverted_index.Administration | 166 |
| abstract_inverted_index.chromatography | 53 |
| abstract_inverted_index.quantification | 36, 87, 205 |
| abstract_inverted_index.simultaneously | 57 |
| abstract_inverted_index.pharmaceuticals | 18 |
| abstract_inverted_index.high‐performance | 51 |
| abstract_inverted_index.third‐generation | 14 |
| abstract_inverted_index.second‐generation | 6 |
| abstract_inverted_index.chromatography‐tandem | 30 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5001263306 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 14 |
| corresponding_institution_ids | https://openalex.org/I203951103 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.44999998807907104 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.85388972 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |